Introduction
-tubulin heterodimers and are involved in many cellular functions such as cell motility, cell division, intracellular transport and cellular architecture (1) . Microtubule dynamics are highly regulated in the cell by a variety of stabilizing and destabilizing molecules (2) . Due to their intense dynamicity during mitosis, MT constitute important targets for anticancer drugs (3) . MT are necessary for the execution and timing of mitosis as well as for the determination of the overall duration of the cell cycle (4) . Microtubule nucleation involves centrosomes that play additional roles such as organization of cytosolic microtubules, formation of spindle microtubules during mitosis and axonemes formation in ciliogenesis (5) (6) (7) . In the absence of centrosomes, the spindle is assembled but cell cleavage is interrupted (8, 9) . Centrosome duplication occurs during Sphase of the cell cycle and is regulated throughout the cell cycle to control their MT nucleation potential (7) . In some breast cancer tumor cells, an accumulation of supernumerary centrosomes has been reported (10).
-tubulin heterodimers requires a folding pathway that involves many protein chaperones and cofactors (11) . Cytosolic chaperonins are highly expressed during cell growth especially from G1/S transition to early S phase and are essential for the folding of actin, tubulin and other cytosolic proteins (12) . The five Tubulin Binding Cofactors (TBC) A to E act at different levels of this pathway to generate polymerizable heterodimers (13) . Many of these cofactors have also been shown to play other roles in regulating microtubule stability and dynamics (14) . TBCD present in the cytoplasm functions as a centrosomal protein -TuRC as well as microtubule growth and mitotic spindle formation. TBCD centrosomal binding partners remain unknown and further studies are to be done to elucidate the regulatory mechanisms behind the recruiting role of TBCD during interphase and mitosis (15) . Little is known regarding the role of TBCs in cancer. It has been 4 shown that the inhibition of TBCA in MCF7 and HeLa cells modified the structure of microtubules and caused cell cycle arrest in G1 (16) . TBCC is an essential and key player -tubulin peptides. A study on POR gene in Arabidopsis thaliana showed that it encodes an ortholog of TBCC and plays an important role in releasing competent polymerizable heterodimers (17, 18) . Conversely there are no data in the literature regarding the relationship between TBCC and the cell cycle or response to antimicrotubule agents in breast cancer cells.
Here we report the consequences of TBCC silencing in the breast cancer line MCF7, in terms of tubulin pool distribution and microtubule dynamics, cell cycle distribution as well as tumorigenic and sensitivity to chemotherapeutic agents in vivo.
Materials and Methods

Plasmid construction
Human TBCC (NM_003192) was amplified with from hTerT-HME-1 human mammary epithelium cells (American Type Culture Collection, ATCC) and the purified amplicon was cloned into pcDNA6 in the antisense orientation (designated as pcDNA6/C-) using EcoRI (Fermentas, France) as described previously (19) .
Cell culture and transfections
MCF7 human mammary adenocarcinoma (ATCC, no authentification was done by the authors) were cultured and transfected with pcDNA6/C-or empty pcDNA6 as previously described (19) Immunofluorescence Cells were processed for Immunofluorescence as previously described (19) . Antibodies used -tubulin 1:100 (clone 2.1, Sigma Aldrich), or TBCC 1:30 (Abnova, Taiw -tubulin 1:50 (clone GTU-88, Sigma Aldrich) followed by secondary FITCantibody (Dako, Denmark). DNA staining was performed using diaminido-phenyl-indol (DAPI) (Roche, Manheim, Germany).
Short pulse BrdU incubation
of BrdU (B5002, Sigma Aldrich) for 5, 15, 30 and 60 minutes. Cells were then collected and labelled with anti-BrdU (347583, Becton Dickinson)
Long time-lapse microscopy and analysis of mitosis Cells (3.10 5 ) were seeded in 35 mm cell culture dish in culture medium maintained at 37°C in a 5% CO 2 atmosphere, time lapse microscope and mitotic analysis were performed as previously described (19) .
Cell proliferation analysis
Cell proliferation was estimated using nonradioactive BrdU based cell proliferation assay hours. Cells (5. 
Cytotoxicity Studies
The IC50 of gemcitabine was defined as the concentration inhibiting proliferation to a level equal to 50% of that of controls. IC50 values were determined by methylthiazoletetrazolium assay from concentration effect curves generated using Microsoft Excel as previously described (20).
RNA interference assays
Desalted duplex siRNA targeting TBCC -CUGAGCAACUGCACGGUCA- 
Analysis of cell cycle distribution by flow cytometry
Cells were collected, incubated 1 hour at 4°C with propidium iodide (0.05 mg/ml) solution containing Nonidet-P40 (0.05%) and analyzed using a FACS Calibur flow cytometer (BD Biosciences Europe, Erembodegem, Belgium) as previously described (19) transfected clones, the cell cycle was studied 48 h after the first transfection. Synchronization of cells at the beginning of S-phase was done by a double thymidine block as previously described by Whitfield et al. 2000 (21) .
In vivo growth analysis
Female CB17/SCID mice purchased from Charles River Laboratories (Arbresle, France) were bred under pathogen-free conditions at the animal facility of our institute and treated as previously described (19) . Animals were treated in accordance with the European Union guidelines for laboratory animal care and use and the study was approved by the local animal ethical committee. All mice used were 5 to 6 weeks old at the time of cells injections. Mice were divided into six groups of six mice injected with six clones. 3. subcutaneously in mice with 50% matrigel (BD Biosciences, Belgium). The six mice were divided into two groups of treated and untreated mice. In the treated groups, gemcitabine (120 mg/kg) was injected intraperitoneally on days 1, 4, 7 and 10. Tumor volumes were measured twice per week and computed with the formula 4/3 (3.14 x r 3 ), r as the mean radius.
Statistical analysis
The statistical significance of the in vivo and in vitro data was determined with a Student's ttest. p<0.05 (*) and p<0.001 (**) indicate a statistically significant and highly significant, respectively.
Results
TBCC protein expression in stable clones
Three clones obtained from MCF7 stably transfected with the empty vector were designated precluding definitive conclusions regarding the impact of TBCC on this protein. We investigated the expression levels of TBCD and ADP-ribosylation factor-like 2 (Arl2) which are also involved in tubulin folding and found that Arl2 was decreased in the three MCclones while TBCD was not modified ( Figure 1A ).
Effect of TBCC content on tubulin pools
The different pools of tubulins were investigated in MP6.1 and MC-1cells, the latter having been chosen since they have the lowest content of TBCC among the available clones. MC-1 cells contained a significantly larger pool of polymerizable tubulin (confirmed both for and tubulin) while the non-polymerizable pool appeared to be slightly reduced (Figure 1 B) . 
Localisation of TBCC in the cytoplasm
Silencing of TBCC increases microtubule dynamics
The effects of TBCC silencing on microtubule dynamic instability were compared in MP6.1
and MC-1 cells 48 h after transient transfection with pAcGFP1-parameters which were significantly modified included the mean rates and lengths of growth and shortening and the mean duration in pause. Mean duration of growth or shortening as the frequencies of rescue and catastrophe were not significantly different between the two types of cells. The overall dynamicity was increased by 44% in MC-1 cells in comparison to control cells (Table 1) . (Fig 4B) . In cells exposed to anti-TBCC siRNA we also observed a significant decrease in the G2/M fraction. 
and P21 were not increased in MC-1 cells as in the case of MP6.1 cells ( Figure 4C ). These results were confirmed by quantification ( Figure 4D ).
Response to gemcitabine in vitro and in vivo
Given the impact of TBCC on cell cycle distribution, we assessed the response of TBCC models to cell cycle targeting agents, such as S-phase and G2-M phase targeting compounds.
We investigated the in vitro response of the cells to gemcitabine in vitro, an S-phase specific antimetabolite. We incubated our cells for one week with 0. 
Discussion
Research on microtubules in cancer cell biology and sensitivity to microtubule-binding agents has essentially focused on polymerized tubulin (microtubules) or the equilibrium between polymerizable tubulin dimers and microtubules (22) . Our results show for the first time that the content of the tubulin chaperone protein TBCC has a profound influence on tubulin pools and microtubule dynamics. We found that the unpolymerizable tubulin pool varied proportionately to TBCC content. In coherence with this observation, cells with reduced TBCC content displayed increased microtubule dynamics. These results are to be compared to our previous observations that cells with increased TBCC content contain less polymerizable tubulin and display reduced microtubule dynamics (19) . Overall these data underline the importance of finetuning essential chaperone activities such as that of TBCC and the consequences of small differences in the content of these key proteins on the microtubule cytoskeleton. It is probable that the relatively small differences in TBCC content (19) . While enhanced tumorigenesis is in keeping with the observation that MC-cells proliferate more rapidly in vitro it is possible that various mechanisms contribute to this phenotype. Of note, cells in which TBCC was silenced also contained less ADP-ribosylation factor like 2 (Arl2) protein, involved in tubulin folding (30). We have previously shown that cells with reduced Arl2 generated more aggressive tumors in scid mice, therefore suggesting that Arl2 modifications in TBCC silenced cells may contribute to the tumor aggressivity phenotype (31).
Reduction of TBCC content was associated with enhanced sensitivity to gemcitabine, an S-phase specific compound, but not to microtubule-targeted agents, both in vivo and in vitro. Increased sensitivity to gemcitabine could be explained by the fact that reduced TBCC content was associated with a higher percentage of cells in S phase. To our knowledge, this is the first report describing a relationship between a cytoskeletal-related protein and sensitivity to gemcitabine, a compound which is widely used in the treatment of solid tumors. This 
